Stay updated on Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial
Sign up to get notified when there's something new on the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page.

Latest updates to the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page
- Check7 days agoChange DetectedThe old and new screenshots show the same page content with no substantive updates to study details, status, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check36 days agoChange DetectedAdded a government-operating-status notice and a version upgrade to v3.2.0; removed the previous v3.1.0 marker.SummaryDifference12%

- Check43 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.3%

- Check57 days agoChange DetectedRevision: v3.0.2 replaces v3.0.1, indicating a patch update; the 'Back to Top' link was removed. No other substantive content changes were detected.SummaryDifference0.7%

- Check64 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.7%

- Check72 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, while several location-related terms have been removed.SummaryDifference14%

Stay in the know with updates to Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page.